A lawsuit has been filed on behalf of a woman who suffered from digitalis toxicity in Birmingham, Alabama after ingesting a tablet of Digitek with twice the amount of digitalis contained in it. Digitek is typically prescribed to treat irregular heartbeat or heart failure. Actavis Totowa and their heart drug Digitek is at the center of the latest recalled drug action by the U. S. Food and Drug Administration. The litigation alleges the double thickness and dosage of the defective Digitek caused her to suffer digitalis toxicity resulting in an adverse reaction including a drop in heart rate, blindness, confusion and incoherent speech. She was hospitalized for more than a month and underwent surgery to implant a heart pacemaker to treat the permanent heart damage she suffered in what is believed to have been caused by the Digitek overdose. The victim's injury occurred only a few weeks prior to April 25, 2008 when the FDA announced a nationwide recall of all Digitek tablets. The suit blames Actavis for failing to heed FDA warnings in July and August of 2006 and February of 2007, that many of the drug products that were produced, manufactured and released to the public by Actavis were adulterated and as a result the drugs were not “the identity, strength, quality and purity they purport to possess.”